A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

NCT03950882 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Fatty Liver

Interventions

DRUG: PXL770
DRUG: Placebo

Sponsor

Poxel SA